Total Valuation
Biofrontera has a market cap or net worth of €14.71M. The enterprise value is €13.97M.
Market Cap€14.71M
Enterprise Value€13.97M
Share Statistics
Biofrontera has 6,076,862 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,076,862
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biofrontera’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -6.58%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.19
Return on Invested Capital (ROIC)-6.58%
Return on Capital Employed (ROCE)-0.07
Revenue Per Employee191.14K
Profits Per Employee29.86K
Employee Count69
Asset Turnover0.64
Inventory Turnover0.61
Valuation Ratios
The current PE Ratio of Biofrontera is ―. Biofrontera’s PEG ratio is 0.00.
PE Ratio―
PS Ratio1.12
PB Ratio0.99
Price to Fair Value0.99
Price to FCF-3.33
Price to Operating Cash Flow-1.33
PEG Ratio0.00
Income Statement
In the last 12 months, Biofrontera had revenue of 13.19M and earned -3.96M in profits. Earnings per share was -0.65.
Revenue13.19M
Gross Profit10.91M
Operating Income-1.02M
Pretax Income-1.22M
Net Income-3.96M
EBITDA-560.00K
Earnings Per Share (EPS)-0.65
Cash Flow
In the last 12 months, operating cash flow was 772.00K and capital expenditures 0.00, giving a free cash flow of 772.00K billion.
Operating Cash Flow772.00K
Free Cash Flow772.00K
Free Cash Flow per Share0.13
Dividends & Yields
Biofrontera pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.07
52-Week Price Change-7.51%
50-Day Moving Average2.42
200-Day Moving Average2.56
Relative Strength Index (RSI)52.76
Average Volume (3m)2.79K
Important Dates
Biofrontera upcoming earnings date is Jun 3, 2026, TBA (Confirmed).
Last Earnings DateMay 28, 2025
Next Earnings DateJun 3, 2026
Ex-Dividend Date―
Financial Position
Biofrontera as a current ratio of 2.43, with Debt / Equity ratio of 127.25%
Current Ratio2.43
Quick Ratio1.77
Debt to Market Cap0.04
Net Debt to EBITDA5.32
Interest Coverage Ratio-73.21
Taxes
In the past 12 months, Biofrontera has paid 5.72M in taxes.
Income Tax5.72M
Effective Tax Rate-4.68
Enterprise Valuation
Biofrontera EV to EBITDA ratio is -21.16, with an EV/FCF ratio of -2.66.
EV to Sales0.90
EV to EBITDA-21.16
EV to Free Cash Flow-2.66
EV to Operating Cash Flow-2.69
Balance Sheet
Biofrontera has €3.08M in cash and marketable securities with €1.15M in debt, giving a net cash position of €1.93M billion.
Cash & Marketable Securities€3.08M
Total Debt€1.15M
Net Cash€1.93M
Net Cash Per Share€0.32
Tangible Book Value Per Share€2.44
Margins
Gross margin is 82.79%, with operating margin of -7.77%, and net profit margin of -30.06%.
Gross Margin82.79%
Operating Margin-7.77%
Pretax Margin-9.27%
Net Profit Margin-30.06%
EBITDA Margin-4.25%
EBIT Margin-9.16%
Analyst Forecast
The average price target for Biofrontera is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast27.97%
EPS Growth Forecast-1432.58%